![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif)
aprepitant![Patient Information Patient Information](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/btn-patient-info.gif) A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin type 3 (5-HT3), dopamine, and corticosteroid receptors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif) | Emend | | ![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif) | Code names: | ![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif) | L-754030 MK-0869 ONO-7436 | | ![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509182515im_/http://www.cancer.gov/images/spacer.gif) |